|
|
15.05.25 - 23:54
|
XFRA: DIVIDEND/INTEREST INFORMATION - 19.05.2025 - BE0003470755 (XETRA)
|
|
Das Instrument SOL BE0003470755 SOLVAY S.A. A EQUITY wird cum Dividende/Zinsen gehandelt am 16.05.2025 und ex Dividende/Zinsen am 19.05.2025
The instrument SOL BE0003470755 SOLVAY S.A. A EQUITY has its pre-dividend/interest day on 16.05.2025 and its ex-dividend/interest day on 19.05.2025...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.10.24 - 13:33
|
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer (GlobeNewswire EN)
|
|
NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the appointment of Lou Barbato, M.D., as Chief Medical Officer (CMO) effective immediately. Dr. Barbato's drug development experience includes senior clinical development and operational roles at Jazz Pharmaceuticals, AbbVie, Biogen, Novartis, and Solvay. He joins Incannex as the company continues to advance its lead clinical-stage programs in obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis....
|
|
|